EDAP TMS Secures EUR 36M Credit Facility from European Investment Bank.

EDAP TMS SA has executed a letter of intent for a EUR 36 million credit facility with the European Investment Bank. Proceeds will support the growth of Focal One Robotic HIFU in Focal Therapy for early-stage prostate cancer, as well as accelerate the development of new clinical indications. The credit facility is expected to close by the end of 2025.

EDAP TMS SA (Nasdaq: EDAP), a leader in robotic energy-based therapies, has secured a letter of intent for a €36 million credit facility from the European Investment Bank (EIB). The financing will support the expansion of Focal One® Robotic HIFU technology for early-stage prostate cancer treatment and accelerate development of new clinical indications [1].

The credit facility, expected to close by the end of 2025, will provide low-interest funding accessible in tranches. CEO Ryan Rhodes highlighted that this strategic financing will strengthen EDAP's balance sheet and help expand access to Focal One Robotic HIFU technology for physicians and patients [1].

EDAP TMS SA, recognized for its robotic energy-based therapies, develops, manufactures, promotes, and distributes worldwide minimally invasive medical devices using ultrasound technology. The company introduced the Focal One® in Europe and the U.S. as the leading prostate focal therapy controlled by urologists, with the potential to expand to multiple indications beyond prostate cancer [1].

The FLAME trial, evaluating the efficacy of focal radiation boost in prostate cancer treatment, found that dose escalation at the location of the primary tumor improved biochemical DFS without additional toxicity. Preliminary results indicated a 50% reduction in biochemical failures at 5 years [2].

This funding will bolster EDAP's efforts to enhance the accessibility and effectiveness of its Focal One Robotic HIFU technology, potentially benefiting millions of patients globally [1].

References:
[1] https://www.stocktitan.net/news/EDAP/edap-announces-letter-of-intent-for-36-million-euro-credit-facility-2ymdylq9plat.html
[2] https://www.medscape.com/viewarticle/focal-radiation-boost-enhances-prostate-cancer-control-2025a1000m71